|
Name |
Zelkovamycin
|
Molecular Formula | C36H45N9O9S | |
IUPAC Name* |
(16Z)-7-acetyl-13-ethyl-16-ethylidene-4-[(7-methoxy-1H-indol-3-yl)methyl]-7,18,22-trimethyl-24-thia-3,6,9,12,15,18,21,26-octazabicyclo[21.2.1]hexacosa-1(25),23(26)-diene-2,5,8,11,14,17,20-heptone
|
|
SMILES |
CCC1C(=O)N/C(=C\C)/C(=O)N(CC(=O)NC(C2=NC(=CS2)C(=O)NC(C(=O)NC(C(=O)NCC(=O)N1)(C)C(=O)C)CC3=CNC4=C3C=CC=C4OC)C)C
|
|
InChI |
InChI=1S/C36H45N9O9S/c1-8-22-30(49)41-23(9-2)34(52)45(6)16-28(48)39-18(3)33-43-25(17-55-33)31(50)42-24(13-20-14-37-29-21(20)11-10-12-26(29)54-7)32(51)44-36(5,19(4)46)35(53)38-15-27(47)40-22/h9-12,14,17-18,22,24,37H,8,13,15-16H2,1-7H3,(H,38,53)(H,39,48)(H,40,47)(H,41,49)(H,42,50)(H,44,51)/b23-9-
|
|
InChIKey |
VYMRECQGDKKGCJ-AQHIEDMUSA-N
|
|
Synonyms |
Zelkovamycin; 221197-33-7; (12Z,16Z)-7-acetyl-13-ethyl-16-ethylidene-4-((7-methoxy-1H-indol-3-yl)methyl)-7,18,22-trimethyl-3,6,9,12,15,18,21-heptaaza-1(2,4)-thiazolacyclodocosaphane-2,5,8,11,14,17,20-heptaone; Zelcovamycin; (16Z)-7-acetyl-13-ethyl-16-ethylidene-4-[(7-methoxy-1H-indol-3-yl)methyl]-7,18,22-trimethyl-24-thia-3,6,9,12,15,18,21,26-octazabicyclo[21.2.1]hexacosa-1(25),23(26)-diene-2,5,8,11,14,17,20-heptone
|
|
CAS | NA | |
PubChem CID | 10395445 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 779.9 | ALogp: | 0.9 |
HBD: | 7 | HBA: | 11 |
Rotatable Bonds: | 5 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 278.0 | Aromatic Rings: | 4 |
Heavy Atoms: | 55 | QED Weighted: | 0.14 |
Caco-2 Permeability: | -5.793 | MDCK Permeability: | 0.00000359 |
Pgp-inhibitor: | 0.76 | Pgp-substrate: | 1 |
Human Intestinal Absorption (HIA): | 0.853 | 20% Bioavailability (F20%): | 0.955 |
30% Bioavailability (F30%): | 0.991 |
Blood-Brain-Barrier Penetration (BBB): | 0.066 | Plasma Protein Binding (PPB): | 75.36% |
Volume Distribution (VD): | 0.228 | Fu: | 38.60% |
CYP1A2-inhibitor: | 0.001 | CYP1A2-substrate: | 0.112 |
CYP2C19-inhibitor: | 0.134 | CYP2C19-substrate: | 0.049 |
CYP2C9-inhibitor: | 0.303 | CYP2C9-substrate: | 0.442 |
CYP2D6-inhibitor: | 0 | CYP2D6-substrate: | 0.113 |
CYP3A4-inhibitor: | 0.261 | CYP3A4-substrate: | 0.45 |
Clearance (CL): | 2.481 | Half-life (T1/2): | 0.721 |
hERG Blockers: | 0.007 | Human Hepatotoxicity (H-HT): | 0.687 |
Drug-inuced Liver Injury (DILI): | 0.822 | AMES Toxicity: | 0.006 |
Rat Oral Acute Toxicity: | 0.674 | Maximum Recommended Daily Dose: | 0.486 |
Skin Sensitization: | 0.063 | Carcinogencity: | 0.008 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.002 |
Respiratory Toxicity: | 0.028 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC004435 | 0.825 | D09ZIO | 0.298 | ||||
ENC004434 | 0.822 | D0X9PF | 0.256 | ||||
ENC004432 | 0.819 | D0M2YE | 0.237 | ||||
ENC004433 | 0.702 | D0L7LC | 0.234 | ||||
ENC005139 | 0.341 | D07DSQ | 0.233 | ||||
ENC005343 | 0.317 | D00TLP | 0.229 | ||||
ENC001987 | 0.307 | D02XIY | 0.229 | ||||
ENC002515 | 0.297 | D0E2OU | 0.220 | ||||
ENC005563 | 0.295 | D0D8XY | 0.213 | ||||
ENC005276 | 0.294 | D07ESC | 0.209 |